Watermark

BGB-3111-218

Completed

Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-3111-218

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20210786

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

No Study Documents

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

No Study Documents